Henry B Koon Jr. MD
Hematologic Oncology, Melanoma, Sarcoma
Clinical Trial Lead, Melanoma
Join to view full profile
Bristol Myers Squibb3401 Princeton PikeLawrenceville, NJ 08648
Dr. Koon is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Henry Koon is an oncologist in Lawrenceville, NJ. He received his medical degree from University of Mississippi School of Medicine and has been in practice 23 years. He specializes in hematologic oncology and is experienced in sarcomas, melanoma and cutaneous malignancies.
Education & Training
University of Mississippi Medical CenterResidency, Internal Medicine, 1994 - 1997- University of Mississippi School of MedicineClass of 1994
Certifications & Licensure
OH State Medical License 2007 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Rhapsody Connect, Orion Health, 2015-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2015-2017
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2015-2017
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsTreatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.Dean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, Michael Schenker, Begoña P Valderrama
Future Oncology. 2023-02-01 - 306 citationsAdjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.Dean F Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama
The New England Journal of Medicine. 2021-06-02 - 22 citationsImmune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen
Journal for Immunotherapy of Cancer. 2021-05-01
Press Mentions
Leap Therapeutics Presents Data from Phase 1 Study of GITR AgonistNovember 12th, 2016- Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual MeetingJune 5th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
